Update for investors of !Zydus

$ZYDUSLIFE is currently trading at Rs. 1194.00, up by 14.00 points or 1.19% from its previous closing of Rs. 1180.00 on the BSE. The scrip opened at Rs. 1198.60 and has touched a high and low of Rs. 1198.60 and Rs. 1151.40 respectively. So far 1.01 lakh shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1205.00 on 11-Aug-2026 and a 52 week low of Rs. 835.85 on 02-Apr-2026. Last one week high and low of the scrip stood at Rs. 1205.00 and Rs. 1093.30 respectively. The current market cap of the company is Rs. 1,19,101.96 crore. The promoters holding in the company stood at 75.01%, while Institutions and Non-Institutions held 18.15% and 6.83% respectively. Zydus Lifesciences’ wholly-owned subsidiary -- Sentynl Therapeutics, Inc. (Sentynl) and Mereo BioPharma Group plc (Mereo), a clinical-stage biopharmaceutical company focused on rare diseases, have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency Associated Lung Disease (AATD-LD). Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States. Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.